Actively Recruiting
Contribution of New Pancreatic MRI Sequences for the Evaluation of Tumor Response in Pancreatic Adenocarcinomas
Led by Central Hospital, Nancy, France · Updated on 2025-07-17
120
Participants Needed
1
Research Sites
104 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Pancreatic adenocarcinoma is the most pessimistic digestive cancer in terms of prognosis. Tumor response assessment is crucial, and the recent development of new magnetic resonance imaging sequences, such as high resolution applied to diffusion sequences (Harder et al., 2022) or magnetic resonance elastography (MRE) (Steinkohl et al., 2021), could help address this issue.
CONDITIONS
Official Title
Contribution of New Pancreatic MRI Sequences for the Evaluation of Tumor Response in Pancreatic Adenocarcinomas
Who Can Participate
Eligibility Criteria
You may qualify if you...
- CT scan diagnosis of non-metastatic pancreatic cancer on contrast-enhanced thoraco-abdomino-pelvic CT;
- Adult patient: age ≥ 18 years;
- Patient affiliated with a social security system or beneficiary of such a system;
- Patient who has received complete information about the research organization and has signed an informed consent form.
You will not qualify if you...
-
Patient with a contraindication to MRI.
-
Person referred to in Articles L. 1121-5, L. 1121-7, and L. 1121-8 of the French Public Health Code.
- Pregnant woman, parturient, or breastfeeding mother;
- Minor (non-emancipated) individual;
- Adult individual under legal protection (guardianship, curatorship, or judicial safeguard);
- Adult individual unable to express consent.
-
Person deprived of liberty by a judicial or administrative decision, or person undergoing psychiatric care pursuant to Articles L. 32-12-1 and L. 3213-1 of the French Public Health Code.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
CHRU Nancy
Vandœuvre-lès-Nancy, France, France, 54511
Actively Recruiting
Research Team
G
Guillaume DROUOT, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
OTHER
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here